Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Isofol Medical AB ( (SE:ISOFOL) ) is now available.
Isofol Medical AB announced its participation in several investor meetings in December and January to present its drug candidate, arfolitixorin. This drug is currently in a phase Ib/II clinical study and has the potential to address a significant treatment gap in cancer care. The company’s CEO, Petter Segelman Lindqvist, will present at various events, highlighting the drug’s potential impact on cancer treatment.
More about Isofol Medical AB
Isofol Medical AB is a biotechnology company focused on enhancing cancer treatment outcomes. The company is developing arfolitixorin, a clinical-stage drug candidate aimed at improving the efficacy of standard cancer treatments, particularly for colorectal cancer, the world’s third most common cancer.
YTD Price Performance: -60.51%
Average Trading Volume: 620,248
Technical Sentiment Signal: Sell
Current Market Cap: SEK216.5M
For detailed information about ISOFOL stock, go to TipRanks’ Stock Analysis page.